Has Victor Echenique, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,018 in general payments to Victor Echenique, MD across 169 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Victor Echenique, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Victor Echenique, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Victor Echenique, MD

Interventional Cardiology · Slidell, LANPI 1518960962

Payments from drug & device makers

$3,018in general payments, 2019–2025

Across 169 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$499
Novartis$338
Johnson & Johnson$286
E.r. Squibb & Sons, L.L.C.$259
Esperion Therapeutics, Inc.$225
Pfizer$215
plus $1K from 21 others

What the payments were for

Food & beverage$3,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	5	$499
Novartis	21	$338
Johnson & Johnson	20	$286
E.r. Squibb & Sons, L.L.C.	15	$259
Esperion Therapeutics, Inc.	13	$225
Pfizer	27	$215
Merck	11	$187
Amgen	10	$154
Sanofi-aventis U.S. LLC	8	$128
Kestra Medical Technology Services, Inc.	5	$101
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$80
Baxter Healthcare	2	$79
AstraZeneca	5	$72
Bayer	3	$50
Irhythm Technologies, Inc.	3	$50
Abbott	3	$49
Amarin Pharma, Inc.	2	$40
Medtronic(2 entities)	2	$34
Inspire Medical Systems, Inc.	2	$33
Kiniksa Pharmaceuticals, Ltd.	1	$22
Itamar Medical Inc	1	$20
Novo Nordisk	1	$19
Boehringer Ingelheim	1	$19
Regeneron Healthcare Solutions, Inc.	1	$17
Sanofi Pasteur Inc.	1	$15
Actelion Pharmaceuticals US, Inc.	1	$14
Kowa Pharmaceuticals America, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,018 in reported general payments places this provider in the 15th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$78,986

Medicare patients

627

Services billed

1,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	374	$341,204
XareltoRivaroxaban	113	$110,166
Repatha SureclickEvolocumab	138	$104,717
EntrestoSacubitril/Valsartan	86	$87,162
MultaqDronedarone Hcl	25	$34,761
Metoprolol Succinate	485	$5,888
Ezetimibe	197	$4,401
Rosuvastatin Calcium	317	$3,831
Losartan Potassium	250	$2,639
Potassium Chloride	171	$2,479
Propafenone Hcl ErPropafenone Hcl	15	$2,375
ClopidogrelClopidogrel Bisulfate	195	$2,062
Nebivolol Hcl	54	$2,049
Bisoprolol Fumarate	119	$1,988
Amiodarone Hcl	85	$1,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$215	$341,204374 claims
Johnson & JohnsonXarelto	$286	$110,166113 claims
NovartisEntresto	$338	$87,16286 claims
Sanofi-aventis U.S. LLCMultaq	$128	$34,76125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 171 interventional cardiology providers in Louisiana.